301015 百洋医药
已收盘 02-24 15:00:00
资讯
新帖
简况
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液目前审评处于暂停状态
证券之星 · 02-12
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液目前审评处于暂停状态
百洋医药为子公司天津百洋、上海制药提供担保
中金财经 · 01-30
百洋医药为子公司天津百洋、上海制药提供担保
百洋医药：聚焦医学创新成果开发与商业化
证券之星 · 01-16
百洋医药：聚焦医学创新成果开发与商业化
百洋医药股东会通过关联投资及日常关联交易议案
中金财经 · 01-15
百洋医药股东会通过关联投资及日常关联交易议案
青岛百洋医药股份有限公司股东会通过关联投资及交易议案
中金财经 · 01-15
青岛百洋医药股份有限公司股东会通过关联投资及交易议案
股市必读：百洋医药（301015）1月9日董秘有最新回复
证券之星 · 01-12
股市必读：百洋医药（301015）1月9日董秘有最新回复
百洋医药：公司重视市值管理
证券之星 · 01-09
百洋医药：公司重视市值管理
百洋医药：对ZAP-X火星舟放射外科机器人开展独家商业化合作
证券之星 · 01-08
百洋医药：对ZAP-X火星舟放射外科机器人开展独家商业化合作
股市必读：百洋医药（301015）1月6日董秘有最新回复
证券之星 · 01-07
股市必读：百洋医药（301015）1月6日董秘有最新回复
百洋医药（301015）披露2025年第四季度可转换公司债券转股情况，1月6日股价下跌2.58%
证券之星 · 01-06
百洋医药（301015）披露2025年第四季度可转换公司债券转股情况，1月6日股价下跌2.58%
百洋医药：纽特舒玛蝉联进口纯乳清蛋白粉中国销售额第一
证券之星 · 01-06
百洋医药：纽特舒玛蝉联进口纯乳清蛋白粉中国销售额第一
股市必读：百洋医药（301015）1月5日董秘有最新回复
证券之星 · 01-06
股市必读：百洋医药（301015）1月5日董秘有最新回复
百洋医药：宣武-百洋医药神经网络疾病协同创新联合实验室
证券之星 · 01-05
百洋医药：宣武-百洋医药神经网络疾病协同创新联合实验室
1月5日百洋医药涨6.91%，安信医药健康股票A基金重仓该股
证券之星 · 01-05
1月5日百洋医药涨6.91%，安信医药健康股票A基金重仓该股
百洋医药涨6.91%，华源证券二个月前给出“买入”评级
证券之星 · 01-05
百洋医药涨6.91%，华源证券二个月前给出“买入”评级
青岛百洋医药可转债募投项目“百洋云化系统升级项目”再度延期至2027年
中金财经 · 2025-12-31
青岛百洋医药可转债募投项目“百洋云化系统升级项目”再度延期至2027年
百洋医药：易复诊为公司控股股东投资的企业
证券之星 · 2025-12-23
百洋医药：易复诊为公司控股股东投资的企业
百洋医药（301015）披露子公司为子公司提供担保的进展公告，12月19日股价上涨0.73%
证券之星 · 2025-12-19
百洋医药（301015）披露子公司为子公司提供担保的进展公告，12月19日股价上涨0.73%
百洋医药：戈芮宁纳入商保创新药目录
证券之星 · 2025-12-09
百洋医药：戈芮宁纳入商保创新药目录
百洋医药：河北百洋萨普为公司全资子公司与Zap Therapeutic Solutions Limited合资企业
证券之星 · 2025-12-09
百洋医药：河北百洋萨普为公司全资子公司与Zap Therapeutic Solutions Limited合资企业
暂无数据
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是药品、医疗器械、其他产品、品牌服务、其他服务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":24.21,"timestamp":1771916625000,"preClose":23.4,"halted":0,"volume":9358022,"delay":0,"changeRate":0.0346,"floatShares":526000000,"shares":526000000,"eps":1.0027,"marketStatus":"已收盘","change":0.81,"latestTime":"02-24 15:00:00","open":23.56,"high":24.94,"low":23.55,"amount":229000000,"amplitude":0.0594,"askPrice":24.23,"askSize":247,"bidPrice":24.21,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.0027,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":5,"adr":0,"adjPreClose":23.4,"symbolType":"stock","openAndCloseTimeList":[[1771896600000,1771903800000],[1771909200000,1771916400000]],"highLimit":25.74,"lowLimit":21.06,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":5.16,"roa":"--","peRate":24.144809,"roe":"20.25%","epsLYR":1.32,"committee":-0.21608,"marketValue":12725000000,"turnoverRate":0.0178,"status":0,"floatMarketCap":12724000000},"requestUrl":"/m/hq/s/301015/tweets","defaultTab":"tweets","newsList":[{"id":"2610591480","title":"百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液目前审评处于暂停状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2610591480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610591480?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:00","pubTimestamp":1770879645,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)02月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，“锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液”现在什么情况了？快3个月了一直暂停着，还在等待专家会议吗？百洋医药回复：投资者您好，锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液目前审评处于暂停状态，属于正常审评流程，后续进展请关注国家药品审评中心（CDE）官网，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200018840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2607090816","title":"百洋医药为子公司天津百洋、上海制药提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2607090816","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607090816?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:30","pubTimestamp":1769761828,"startTime":"0","endTime":"0","summary":"中访网数据 青岛百洋医药股份有限公司于近日披露了为子公司提供担保的进展。根据此前股东大会授权，公司为控股子公司天津百洋医药有限公司向中国光大银行青岛分行申请的综合授信提供了连带责任保证担保，担保主债权最高本金余额为1,000万元。公司表示，被担保子公司经营稳定，资信状况良好，担保风险可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260130/31986748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01477","BK1574","301015","BK1191","BK0250"],"gpt_icon":0},{"id":"2603699542","title":"百洋医药：聚焦医学创新成果开发与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603699542?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:51","pubTimestamp":1768567891,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：AI已广泛用于诊断查体治疗等医疗领域应用。贵司是否有相关落地场景，如有，请阐述下。百洋医药回复：投资者您好，公司核心业务聚焦医学创新成果的开发、生产与商业化全链条，始终以科技创新为核心驱动力，持续关注包括人工智能在内的前沿技术在医疗领域的应用潜力，并积极探索将创新科技与公司业务相融合，推动医疗场景的优化升级。感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600038711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2603608961","title":"百洋医药股东会通过关联投资及日常关联交易议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608961","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603608961?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:13","pubTimestamp":1768468399,"startTime":"0","endTime":"0","summary":"本次会议共有88名股东及代表参与投票，代表有效表决股份2,201,185股，占公司有表决权股份总数的0.4188%，全部通过网络投票方式进行。第二项为《关于2025年度关联交易确认及2026年度日常关联交易预计的议案》，该议案获得1,868,085股同意，占出席会议有效表决权股份的84.8672%。此次股东会的决议标志着百洋医药在关联投资及未来一年日常关联交易安排上获得了股东会的正式授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260115/31945328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2603539608","title":"青岛百洋医药股份有限公司股东会通过关联投资及交易议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2603539608","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603539608?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:13","pubTimestamp":1768468393,"startTime":"0","endTime":"0","summary":"中访网数据 青岛百洋医药股份有限公司于2026年1月15日以现场结合网络方式召开了2026年第一次临时股东会。 会议审议并通过了两项关联交易相关议案。 上述议案的通过，标志着公司关于与专业投资机构共同投资的关联交易以及2026年度日常关联交易预计获得了股东大会的正式批准，相关交易将按计划推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260115/31945314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2602557494","title":"股市必读：百洋医药（301015）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602557494","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602557494?lang=zh_cn&edition=full","pubTime":"2026-01-12 02:44","pubTimestamp":1768157049,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百洋医药报收于25.02元，上涨1.25%，换手率1.27%，成交量6.69万手，成交额1.66亿元。目前合资工厂已正式启用，商业化运营正有序推进。当日关注点来自交易信息汇总：1月9日主力资金净流入544.65万元，显示主力对百洋医药的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2602375032","title":"百洋医药：公司重视市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375032","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375032?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:51","pubTimestamp":1767963093,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，留意到贵司ESG评级很高，仅此有几大医药巨头，但贵司股价市值确才百亿，对此贵司是否有增持以及回购股份进行市值管理等举措呢百洋医药回复：投资者您好，公司 ESG 高评级体现长期发展价值，市值受多重因素影响。公司重视市值管理，您的建议我们会反馈给公司管理层，回购、增持等举措将结合经营及合规要求审慎评估，相关进展请以公告为准，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2601354987","title":"百洋医药：对ZAP-X火星舟放射外科机器人开展独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2601354987","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601354987?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:54","pubTimestamp":1767862449,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司运营的ZAP-X火星舟放射外科机器人，公司负责生产吗？一年产值规模有多少？百洋医药回复：投资者您好，公司自2024年7月公司陆续对Zap Medical System, Ltd.进行产业投资，并对ZAP-X火星舟放射外科机器人开展独家商业化合作、制造服务等一系列合作，合资工厂已正式启用，年产值规模请关注公司后期定期报告，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800026312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2601636812","title":"股市必读：百洋医药（301015）1月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601636812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601636812?lang=zh_cn&edition=full","pubTime":"2026-01-07 02:09","pubTimestamp":1767722950,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，百洋医药报收于24.58元，下跌2.58%，换手率2.07%，成交量10.87万手，成交额2.72亿元。公司公告汇总关于2025年第四季度可转换公司债券转股情况的公告青岛百洋医药股份有限公司发布关于2025年第四季度可转换公司债券转股情况的公告。2025年第四季度，共有9张“百洋转债”完成转股，转股数量为35股。截至2025年12月31日，累计140,769张“百洋转债”转股，合计转成524,077股。公司总股本因转股增加35股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700000960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2601813479","title":"百洋医药（301015）披露2025年第四季度可转换公司债券转股情况，1月6日股价下跌2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813479","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601813479?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:24","pubTimestamp":1767709464,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，百洋医药报收于24.58元，较前一交易日下跌2.58%，最新总市值为129.2亿元。该股当日开盘24.8元，最高26.17元，最低24.56元，成交额达2.72亿元，换手率为2.07%。近日，青岛百洋医药股份有限公司发布关于2025年第四季度可转换公司债券转股情况的公告。2025年第四季度，共有9张“百洋转债”完成转股，转股数量为35股。截至2025年12月31日，累计140,769张“百洋转债”转股，合计转成524,077股。公司总股本因转股增加35股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2601861887","title":"百洋医药：纽特舒玛蝉联进口纯乳清蛋白粉中国销售额第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2601861887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601861887?lang=zh_cn&edition=full","pubTime":"2026-01-06 15:00","pubTimestamp":1767682839,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：减肥药市场火热，公司有没有布局glp-1类减肥产品？百洋医药回复：投资者您好，公司尚未布局glp-1减肥类产品，临床证据显示，超过30%的患者在使用GLP-1类药物出现了显著的体重下降，导致了肌肉流失，口服乳清蛋白是目前公认的最佳营养干预手段之一。公司自有品牌纽特舒玛蝉联进口纯乳清蛋白粉中国销售额第一，可以为这类患者提供更好的营养支持。感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600019701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2601836911","title":"股市必读：百洋医药（301015）1月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601836911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601836911?lang=zh_cn&edition=full","pubTime":"2026-01-06 01:27","pubTimestamp":1767634029,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，百洋医药报收于25.23元，上涨6.91%，换手率1.58%，成交量8.32万手，成交额2.01亿元。当日关注点来自交易信息汇总：1月5日主力资金净流入3124.6万元，显示主力对百洋医药的积极介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600000860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2601001792","title":"百洋医药：宣武-百洋医药神经网络疾病协同创新联合实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=2601001792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601001792?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:45","pubTimestamp":1767602719,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药01月05日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500021962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2601006569","title":"1月5日百洋医药涨6.91%，安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006569","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006569?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:46","pubTimestamp":1767599194,"startTime":"0","endTime":"0","summary":"证券之星消息，1月5日百洋医药涨6.91%，收盘报25.23元，换手率1.58%，成交量8.32万手，成交额2.01亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为安信基金的安信医药健康股票A。安信医药健康股票A目前规模为4.13亿元，最新净值1.3606，较上一交易日下跌0.82%，近一年上涨49.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2601599006","title":"百洋医药涨6.91%，华源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601599006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601599006?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:46","pubTimestamp":1767599189,"startTime":"0","endTime":"0","summary":"今日百洋医药涨6.91%，收盘报25.23元。2025年11月5日，华源证券研究员刘闯发布了对百洋医药的研报《品牌运营业务稳健，创新战略转型下利润短期承压》，该研报对百洋医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为61.17%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为天风证券的杨松。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"gpt_icon":0},{"id":"2595741439","title":"青岛百洋医药可转债募投项目“百洋云化系统升级项目”再度延期至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=2595741439","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595741439?lang=zh_cn&edition=full","pubTime":"2025-12-31 09:34","pubTimestamp":1767144844,"startTime":"0","endTime":"0","summary":"中访网数据 青岛百洋医药股份有限公司于2025年12月30日召开董事会，审议通过了关于部分募投项目延期的议案。公司决定将2023年向不特定对象发行可转换公司债券的募投项目之一——“百洋云化系统升级项目”达到预定可使用状态的时间，由原计划的2025年12月31日进一步延期至2027年2月28日。另一募投项目“百洋品牌运营中心建设项目”已于2024年10月暂缓实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251231/31906732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2593454335","title":"百洋医药：易复诊为公司控股股东投资的企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2593454335","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593454335?lang=zh_cn&edition=full","pubTime":"2025-12-23 08:46","pubTimestamp":1766450774,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，最近蚂蚁阿福带动的AI健康管理如火如荼，可以说是开辟了医药商业的新场景。公司也曾开发易复诊健康管理系统，现业务进展如何？另公司与蚂蚁阿福有合作吗？百洋医药回复：投资者您好，易复诊为公司控股股东投资的企业，目前公司未与蚂蚁阿福合作，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300006149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2592198412","title":"百洋医药（301015）披露子公司为子公司提供担保的进展公告，12月19日股价上涨0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592198412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592198412?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:40","pubTimestamp":1766155206,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，百洋医药报收于23.37元，较前一交易日上涨0.73%，最新总市值为122.84亿元。公司近日发布公告称，控股子公司上海百洋制药股份有限公司为其全资子公司上海百洋制药科技有限公司向招商银行上海分行申请的5,000万元综合授信提供连带责任保证担保。担保后，百洋制药对上海制药的担保余额为6,910.60万元，上海制药可用担保额度为22,000万元。公司及控股子公司无逾期担保，未对合并报表外单位提供担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2590318086","title":"百洋医药：戈芮宁纳入商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318086","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590318086?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:24","pubTimestamp":1765265068,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：报道称北海康城的戈芮宁纳入2025年商保创新药目录，对公司有何影响？ 百洋医药回复：投资者您好，戈芮宁作为国内首个本土自主研发生产的酶替代一类创新药被纳入《商保创新药目录》，将进一步减轻戈谢病患者的用药负担，提升药品可及性，有利于该药品的市场推广及未来销售，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900018333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK1574","159992","301015","BK1161","06978"],"gpt_icon":0},{"id":"2590318083","title":"百洋医药：河北百洋萨普为公司全资子公司与Zap Therapeutic Solutions Limited合资企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318083","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590318083?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:24","pubTimestamp":1765265068,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，百洋ZAP合资工厂是属于上市公司的，还是集团的？百洋医药回复：投资者您好，河北百洋萨普医疗设备科技有限公司系公司全资子公司与Zap Therapeutic Solutions Limited合资的企业，具体信息详见公司于2025年11月19日披露的《关于关联方向全资子公司增资暨关联交易的公告》，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900018329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771942303314,"stockEarnings":[{"period":"1week","weight":-0.0242},{"period":"1month","weight":-0.0795},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.1062},{"period":"1year","weight":0.0159},{"period":"ytd","weight":-0.0085}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"11136人(较上一季度减少40.83%)","perCapita":"47194股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 青岛百洋医药股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是药品、医疗器械、其他产品、品牌服务、其他服务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}